Starting on:
Sep 15, 2026
Ending on:
Sep 15, 2026
Moderator(s):
Zoom Webinar ID: 840 2315 3339
Max Credits:
3 Points
Provider:
Kenya Psychiatrists Association
Claim Points
Sep 15, 2026
Ending on:
Sep 15, 2026
Moderator(s):
Dr.
Pius Kigamwa
Senior lecturer at the University of Nairobi and Consultant Psychiatrist at Nairobi Hospital
Dr. Maureen Wambui
Psychiatry Resident at UoN
Venue: Senior lecturer at the University of Nairobi and Consultant Psychiatrist at Nairobi Hospital
Dr. Maureen Wambui
Psychiatry Resident at UoN
Zoom Webinar ID: 840 2315 3339
Max Credits:
3 Points
Provider:
Kenya Psychiatrists Association
Claim Points
Beyond Dopamine Blocakade; The science of Partial aginism in clinical psychiatry
Starting on:
Sep 15, 2026
Sep 15, 2026
Ending on:
Sep 15, 2026
Sep 15, 2026
Venue:
Zoom Webinar ID: 840 2315 3339
Zoom Webinar ID: 840 2315 3339
Description
This webinar will explore the evolving role of dopamine partial agonism in modern psychiatric treatment, moving beyond traditional dopamine receptor blockade. It will examine the neuropharmacological mechanisms, clinical applications, and therapeutic benefits of partial agonists in managing psychiatric disorders, particularly schizophrenia and bipolar disorder. Emphasis will be placed on their efficacy, tolerability, safety profiles, and implications for individualized, evidence-based psychiatric care.
Objectives
By the end of the webinar, participants should be able to:
1. Understand the neurobiological principles of dopamine receptor partial agonism and how they differ from traditional dopamine antagonism.
2. Explain the mechanisms of action of partial agonist antipsychotics and their effects on dopaminergic neurotransmission.
3. Evaluate the clinical efficacy and safety profiles of partial agonists in managing schizophrenia, bipolar disorder, and other relevant psychiatric conditions.
4. Identify potential advantages and limitations of partial agonists, including their effects on metabolic health, prolactin levels, movement disorders, and treatment adherence.
5. Apply evidence-based principles when selecting and optimizing partial agonist therapies to improve patient outcomes and support individualized psychiatric care.
Presenters
-
Dr.
Lawrence Nderi
Consultant psychiatrist and the current CEO of MNTRH
MNTRH